Navigation Links
NIH Clinical and Translational Science Consortium grows to 39 members
Date:4/7/2009

The National Institutes of Health announced today that the University of Cincinnati will become the 39th member of its Clinical and Translational Science Award (CTSA) consortium. Led by the National Center for Research Resources (NCRR), part of the NIH, this national network of medical research institutions is working together to accelerate the process of turning laboratory discoveries into treatments for patients, to engage communities in clinical research efforts and to train the next generation of clinical and translational researchers.

The consortium was launched in 2006, with new members added in 2007 and 2008. Approximately 60 CTSAs will be connected when the program is fully implemented in 2012. NCRR will award additional CTSA grants this year; more awards are expected in the next several months.

In this latest award, the University of Cincinnati will receive $22.7 million over five years. The new Center for Clinical and Translational Science and Training will expand its support for pediatric research through the Cincinnati Children's Hospital Medical Center; enhance new translational technologies, including large-scale studies of proteins (proteomics), drug discovery, imaging, nanomedicine, gene transfer and stem cell biology. The center also will increase outreach into the local community, including collaborations with the Cincinnati Veterans Affairs Medical Center. Additional information about the grant can be found at http://www.ncrr.nih.gov/cincinnati_ctsa.asp.

"Among the many strengths of this newest CTSA consortium member is the depth of pediatric research conducted at the Cincinnati Children's Hospital one of the top pediatric research hospitals in the nation," said NCRR Director Barbara Alving, M.D. "As part of this national clinical and translational research network, the University of Cincinnati will focus on both pediatric and adult diseases and will increase the breadth of consortium activity throughout the Midwest, bringing research advances into the communities it serves."

Since its launch in 2006, the consortium has been:

  • training researchers in the complexities of clinical and translational research through nationally recognized degree-granting programs;
  • leveraging CTSA resources to expand research and training opportunities in underserved states and communities;
  • assembling interdisciplinary teams that include but are not limited to basic scientists, biologists, clinical researchers, dentists, veterinarians, nurses, pharmacists, biomedical engineers and geneticists;
  • partnering with researchers at minority institutions to enhance outreach to underserved populations, local community and advocacy organizations, and health care providers;
  • creating best practices to improve clinical research informatics tools to analyze research data and manage clinical trials;
  • designating technologies for marketing and licensing purposes that will increase global access to research tools; and
  • forging new partnerships with private and public health care organizations, including pharmaceutical companies, Departments of Veterans Affairs hospitals, and health maintenance organizations, as well as state health agencies.


'/>"/>

Contact: NCRR Office of Communications
info@ncrr.nih.gov
301-435-0888
NIH/National Center for Research Resources
Source:Eurekalert

Related biology news :

1. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
2. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
3. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
4. Cleveland Clinic leading clinical program to improve early-stage lung cancer detection
5. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
6. Study of African traditional medicine will begin world-first clinical trial
7. New clinical data shows chromium picolinate improves cognitive function
8. New clinical trial results show how personalized medicine will alter treatment of genetic disorders
9. Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
10. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
11. NHLBI issues first US von Willebrand Disease clinical practice guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology: